Data collected before and after continuing medical education on the management of familial hypercholesterolemia (HoFH) showed that provider knowledge and competence was notable improved after the session. A poster session presented at the 2023 National Lipid Association Scientific Sessions demonstrated that CME that included patient voice enhanced the ability of providers to adapt to the changing HoFH treatment landscape.
PlatformQ Health developed the session in partnership with the nonprofit organizations the National Infusion Center Association and Mended Hearts. Panelists included the Director of Preventive Cardiology at Brigham & Women’s Hospital and the Chief of the Section of Cardiovascular Research at Baylor College of Medicine. The faculty were joined by a patient, who shared how HoFH affects her daily life and what her treatment journey has been.
The digital education addressed:
- Understanding how to diagnose HoFH earlier
- Strategies for addressing patient barriers related to disease management
- The role of novel mechanisms of action
- Increasing access to infused therapies
There were 1,392 learners in the program, 56% of whom were cardiology specialists.
Post-session surveys showed a positive impact on providers’ knowledge in key areas, including recognition of HoFH symptoms, mechanisms of action of evinacumab, as well as clinical trial outcomes. 79 intended practice changes were reported, which encompassed:
- 62% related to diagnosis and treatment
- 16% related to interdisciplinary care
- 18% related to treatment decision-making
- 4% related to shared decision-making
This data demonstrates the value of CME education for providers in a field like HoFH that is rapidly changing, as well as the need for ongoing education in the treatment of children and adults with the disease.